Edition:
United Kingdom

Molecular Templates Inc (MTEM.OQ)

MTEM.OQ on NASDAQ Stock Exchange Capital Market

7.28USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,221
52-wk High
$11.88
52-wk Low
$3.90

Select another date:

Tue, Nov 14 2017

BRIEF-Molecular Templates appoints Adam Cutler as CFO

* Molecular Templates strengthens management team with appointment of Adam Cutler as Chief Financial Officer

BRIEF-Molecular Templates Q3 loss per share $0.62

* Molecular Templates, Inc. Reports third quarter 2017 financial results

BRIEF-AbCheck and Molecular Templates collaborate to discover therapeutic oncology leads

* Says Abcheck will use Absieve discovery platform to deliver antibodies against biological targets selected by Molecular Templates​

BRIEF-Molecular Templates files for sale of 11.6 mln shares of common stock by selling stockholders‍​

* Molecular Templates Inc - files for sale of 11.6 million shares of common stock by selling stockholders - sec filing‍​ Source text: (http://bit.ly/2x68onC) Further company coverage:

BRIEF-Molecular Templates Inc files to say it raised $20 mln in equity financing‍​

* Molecular Templates Inc files to say it raised $20 million in equity financing‍​ Source text (http://bit.ly/2i1OaYC) Further company coverage:

BRIEF-SHV Management Services reports 32.6 pct stake in Molecular Templates

* SHV Management Services reports 32.6 percent stake in molecular templates as of Aug 1 - SEC filing Source text: (http://bit.ly/2w4gAXS) Further company coverage:

BRIEF-Takeda Pharmaceutical Co reports 10.9 pct stake in Molecular Templates - SEC Filing‍​

* Takeda Pharmaceutical Company reports 10.9 percent stake in Molecular Templates Inc as of August 1, 2017 - SEC Filing‍​ Source text: (http://bit.ly/2vTAtQL) Further company coverage:

BRIEF-Takeda Pharmaceutical and Molecular Templates announce research and licensing collaboration

* Takeda Pharmaceutical and molecular templates announce multi-target research and licensing collaboration to develop next-generation oncology therapies​

Select another date: